Diagnosis and treatment of hepatocellular carcinoma

被引:1032
作者
El-Serag, Hashem B. [1 ]
Marrero, Jorge A. [2 ]
Rudolph, Lenhard [4 ,5 ]
Reddy, K. Rajender [3 ]
机构
[1] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA
[2] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA
[3] Univ Penn, Div Gastroenterol & Hepatol, Philadelphia, PA 19104 USA
[4] Univ Ulm, Inst Mol Med, Ulm, Germany
[5] Univ Ulm, Max Planck Res Grp Stem Cell Aging, Ulm, Germany
关键词
D O I
10.1053/j.gastro.2008.02.090
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The diagnosis and treatment of hepatocellular carcinoma (HCC) have witnessed major changes over the past decade. Until the early 1990s, HCC was a relatively rare malignancy, typically diagnosed at an advanced stage in a symptomatic patient, and there were no known effective palliative or therapeutic options. However, the rising incidence of HCC in several regions around the world coupled with emerging evidence for efficacy of screening in high-risk patients, liver transplantation as a curative option in select patients, ability to make definitive diagnosis using high-resolution imaging of the liver, less dependency on obtaining tissue diagnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliative therapy have improved the outlook for HCC patients. In this article, we present a summary of the most recent information on screening, diagnosis, staging, and different treatment modalities of HCC, as well as our recommended management approach.
引用
收藏
页码:1752 / 1763
页数:12
相关论文
共 107 条
[1]  
Adam R, 2003, ANN SURG, V238, P508, DOI 10.1097/01.sla.0000090449.87109.44
[2]  
Arguedas MR, 2003, AM J GASTROENTEROL, V98, P679, DOI 10.1111/j.1572-0241.2003.07327.x
[3]  
Bayati N, 1998, AM J GASTROENTEROL, V93, P2452, DOI 10.1111/j.1572-0241.1998.00703.x
[4]   Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis [J].
Bolondi, L ;
Sofia, S ;
Siringo, S ;
Gaiani, S ;
Casali, A ;
Zironi, G ;
Piscaglia, F ;
Gramantieri, L ;
Zanetti, M ;
Sherman, M .
GUT, 2001, 48 (02) :251-259
[5]   Chemoembolization for hepatocellular carcinoma [J].
Bruix, J ;
Sala, M ;
Llovet, JM .
GASTROENTEROLOGY, 2004, 127 (05) :S179-S188
[6]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[7]   Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure [J].
Bruix, J ;
Castells, A ;
Bosch, J ;
Feu, F ;
Fuster, J ;
GarciaPagan, JC ;
Visa, J ;
Bru, C ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (04) :1018-1022
[8]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[9]   New aspects of diagnosis and therapy of hepatocellular carcinoma [J].
Bruix, J ;
Hessheimer, AJ ;
Forner, A ;
Boix, L ;
Vilana, R ;
Llovet, JM .
ONCOGENE, 2006, 25 (27) :3848-3856
[10]   MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation:: An explant correlation [J].
Burrel, M ;
Llovet, JM ;
Ayuso, C ;
Iglesias, C ;
Sala, M ;
Miquel, R ;
Caralt, T ;
Ayuso, JR ;
Solé, M ;
Sanchez, M ;
Brú, C ;
Bruix, J .
HEPATOLOGY, 2003, 38 (04) :1034-1042